Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Adastra Holdings Ltd C.XTRX

Alternate Symbol(s):  XTXXF

Adastra Holdings Ltd. is a Canada-based company, which is engaged in the supply and manufacturing of ethnobotanical and cannabis products for lawful adult-use. The Company extracts and processes cannabis for sale to the recreational and medical markets in Canada using its large-scale extraction facility (the Facility) to produce a variety of products, including vape pens, wax, resin, infused pre-rolls, diamonds and shatter. It serves medical markets and engages in therapeutic applications. With cannabis concentrate products sold through retailers at more than 2,000 locations across Canada, Adastra's Phyto Extractions and Endgame Extracts brands are well established with a solid distribution presence. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. Its subsidiaries include Adastra Labs Holdings (2019) Ltd., Adastra Labs Inc., 1178562 B.C. Ltd., Adastra Brands Inc., and others.


CSE:XTRX - Post by User

Comment by lscfaon Mar 10, 2023 3:45pm
118 Views
Post# 35331558

RE:Shareholder Class Action Investigation

RE:Shareholder Class Action InvestigationNo merit to lawsuit. The Feb 22 NR made it clear that Adastra was limited to very small quantities so it is not reasonable for a reader to assume large scale selling to the public was feasible. 



"The amended license allows Adastra to interact with up to 250 grams of cocaine and to import coca leaves to manufacture and synthesize the substance."
<< Previous
Bullboard Posts
Next >>